Rolls ends 'thrilling' rights issue after vaccine boost

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Rolls ends 'thrilling' rights issue after vaccine boost

rolls_royce_aerospace_Adobe_575x375_sep21
Emblem of the Rolls-Royce on the engine of the Trent XWB of the wide-body jet airliner Airbus A350 XWB, on April 25, 2018 in Berlin, Germany. | Sergey Kohl/Sergey Kohl - stock.adobe.com

Rolls-Royce, the UK aerospace company, completed its rights issue on Thursday, with the cash call proving to be a resounding success. The deal benefited from a late boost on Monday, when US drug company Pfizer said it had enjoyed successful late-stage trials for a Covid-19 vaccine, giving investors hope that Rolls-Royce engines would be powering more planes into the sky sooner than expected.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article